Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 Recruiting
81 enrolled
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Phase 2 Recruiting
165 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 Recruiting
75 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
PROPS GYN
Phase 2 Recruiting
25 enrolled
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 Recruiting
148 enrolled
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Phase 2 Recruiting
20 enrolled
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Phase 2 Recruiting
114 enrolled
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2 Recruiting
25 enrolled
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2 Recruiting
393 enrolled
A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 Recruiting
100 enrolled
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 Recruiting
60 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2 Recruiting
20 enrolled
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Phase 2 Recruiting
86 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 Recruiting
87 enrolled
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Phase 2 Recruiting
24 enrolled
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Phase 2 Recruiting
25 enrolled
Electrochemotherapy for Recurrent Vulvar Cancer
Phase 2 Recruiting
13 enrolled
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Phase 2 Recruiting
48 enrolled
Charlie-2
Phase 2 Recruiting
200 enrolled
INTLECTUAL
Phase 2 Recruiting
17 enrolled
DEHIM_CCRT
Phase 2 Recruiting
34 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
Phase 2 Recruiting
37 enrolled
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
Phase 2 Recruiting
30 enrolled
IPROC
Phase 2 Recruiting
60 enrolled
N-Plus
Phase 2 Recruiting
640 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2 Recruiting
25 enrolled
DENALI
Phase 2 Recruiting
170 enrolled
ALPINE: Maintenance Letrozole/Abemaciclib
Phase 2 Recruiting
32 enrolled
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Phase 2 Recruiting
50 enrolled
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 2 Recruiting
43 enrolled
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Phase 2 Recruiting
20 enrolled
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 Recruiting
492 enrolled
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Phase 2 Recruiting
62 enrolled
CHAMELEON
Phase 2 Recruiting
20 enrolled
A Study of Isoquercetin in People With Ovarian Cancer
Phase 2 Recruiting
90 enrolled
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 Recruiting
740 enrolled
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Phase 2 Recruiting
33 enrolled
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Phase 2 Recruiting
353 enrolled
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Phase 2 Recruiting
96 enrolled
Uterine Preservation Via Lifestyle Transformation
Phase 2 Recruiting
96 enrolled
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Phase 2 Recruiting
86 enrolled
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Phase 2 Recruiting
45 enrolled